Newsletter michelnizon.com - 2ème saison : Boundless Bio, Inc.

Désignation : Boundless Bio

Code Mnémonique : Bold

Date de Création : 2018

Bourse américaine : Nasdaq

Date d’Introduction : 28 mars 2022

Cours d’Introduction : 16 dollars

Site : boundlessbio.com

We are a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. (page 1 du prospectus)

We aspire to improve clinical outcomes for patients with oncogene amplified cancer by developing drugs that interfere with the formation and function of ecDNA in cancer cells. (page 117 du prospectus)

Le cours de l’action BOLD ce vendedi matin est en dessous de celui de l’introduction….

Communauté (-)

En bas de sa page d’accueil :

Twitter : 346 abonnés ce vendredi matin. Le dernier tweet remonte au 28 mars 2024 lié à son IPO.

Linkedin : 6K followers

Si ce second chiffre est plus que correct, ce n’est pas le cas pour le premier.

Faisabilité (-)

Boundless Bio, Inc n’a pas dépassé les phases 1/2 des essais cliniques pour valider ses travaux de recherche… :

We are a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. (page 1 du prospectus)

We expect to have preliminary clinical proof of concept safety and antitumor activity data of BBI-825 in combination with targeted therapies from the STARMAP clinical trial in the second half of 2025. (page 4 du prospectus)

Modèle Économique (-)

Boundless Bio, Inc. accumule les pertes :

We have incurred significant operating losses since our inception and, as of December 31, 2023, we had an accumulated deficit of $136.1 million. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, seek regulatory approval for, and potentially commercialize any of our ecDTx and seek to discover and develop additional ecDTx, develop our ecDNA diagnostic, conduct our ongoing and planned clinical trials and preclinical studies, continue our research and development activities, utilize third parties to manufacture our ecDTx and related raw materials, hire additional personnel, expand and protect our intellectual property, as well as incur additional costs associated with being a public company. (page 88 du prospectus)

We do not have any products approved for sale and have not generated any revenue to date. (page 88 du prospectus)

(in thousands)

Net loss 2022   $ (45,901 ) - 2023  $ (49,434 ) (page 91 du prospectus)

Bien que l’équipe semble compétente, elle n’a pas pas démontré de Skin in the Game.

Le chemin de la profitabilité reste très hasardeux…. :

To become and remain profitable, we must succeed in discovering, developing, obtaining regulatory approvals for, and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials and preclinical studies of our ecDTx, discovering additional ecDTx, obtaining regulatory approval for these ecDTx and, if required, our ecDNA diagnostic, and manufacturing, marketing, and selling any products for which we may obtain regulatory approval for these ecDTx and, if required, our ecDNA diagnostic, and manufacturing, marketing, and selling any products for which we may obtain regulatory approval. We are in only the preliminary stages of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability. (page 14 du prospectus)

Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable may have an adverse effect on the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our ecDTx pipeline, achieve our strategic objectives, or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. (page 15 du prospectus)

We are early in our development efforts and have only two ecDTx in clinical development. All of our other ecDTx programs are still in the preclinical or discovery stage. If we are unable to successfully develop, obtain regulatory approval, and ultimately commercialize any of our current or future ecDTx, or experience significant delays in doing so, our business will be materially harmed. (page 17 du prospectus)

Clinical and preclinical development involves a lengthy and expensive process with uncertain timelines and outcomes, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. Our ecDTx may not achieve favorable results in clinical trials or preclinical studies or receive regulatory approval on a timely basis, if at all. (page 19 du prospectus)

La concurrence étant déjà très nombreuse :

We face significant competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms. If our competitors develop and commercialize their product candidates more rapidly than we do, or their technologies or their product candidates are more effective, safer, or less expensive than our ecDTx, our business and our ability to develop and successfully commercialize ecDTx may be adversely affected. (page 37 du prospectus)

Ne voulant pas jouer au Loto, Boundless Bio, Inc. reçoit la note minimale Kd. Vous pouvez télécharger/lire son Certificat de Fast-Kchehcking ici. Je ne comprends pas à ce stade des esssais cliniques que des investisseurs professionnels n’assurent pas seuls cette augmentation de capital.…

Cordialement.

Michel Nizon

Cofondateur/CEO Kchehck, Inc.

PS : N’investissez que dans des Ka+.

Avertissement

Cette newsletter est publiée par Kchehck, Inc qui, selon sa propre méthode brevetée et validée, évalue sur 3 critères principaux, principalement extra financiers, souvent des entreprises de moins de 10 ans en croissance et présentes principalement sur le Nasdaq. Ces analyses ne peuvent constituer en aucun cas des conseils d’achat ou de vente d’actions des sociétés ainsi étudiées mais exclusivement une source d’information supplémentaire pour nourrir votre réflexion entrepreneuriale et micro économique. Les analyses kchehck sont strictement réservées aux investisseurs particuliers pour un usage personnel, et sont interdites aux usages professionnels par des investisseurs institutionnels.